SPL028
≈ 2 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
SPL028, or SPL-028, also known as α,α-dideutero-N,N-dimethyltryptamine (D 2 -DMT), is a psychedelic drug of the tryptamine family which is under development for the treatment of depressive disorders. It is the analogue of dimethyltryptamine (DMT) in which the α carbon has been dideuterated. SPL028's route of administration is intravenous injection or intramuscular injection.
SPL028, or SPL-028, also known as α,α-dideutero-N,N-dimethyltryptamine (D 2 -DMT), is a psychedelic drug of the tryptamine family which is under development for the treatment of depressive disorders. It is the analogue of dimethyltryptamine (DMT) in which the α carbon has been dideuterated. SPL028's route of administration is intravenous injection or intramuscular injection. ==Pharmacology== SPL028 shows similar pharmacodynamics as DMT in vitro. Relatedly, SPL028 generalized with DMT in rodent drug discrimination tests. On the other hand, SPL028 differs from DMT in terms of pharmacokinetics; it is more resistant to metabolism and shows a prolonged duration. In a phase 1 clinical trial, SPL-028 by intramuscular injection produced robust psychedelic effects of short duration in humans. ==Research== SPL028 was originated by Small Pharma and is under development by Cybin. Small Pharma was acquired by Cybin in 2023. As of February 2024, SPL028 is in phase 1 clinical trials. ==See also== Substituted tryptamine List of investigational hallucinogens and entactogens Deudimethyltryptamine (DMT-d10; HLP004; CYB004) Deuterated 5-MeO-DMT α,α-Dideuterotryptamine ==References== ==External links== D 2 -DMT (SPL028) - Isomer Design
Text derived from https://en.wikipedia.org/w/index.php?oldid=1366889394 under CC BY-SA 4.0; modifications have been made.